HN2002000289A - 2-amino-6-(fenilo sustituido en las posiciones 2, 4, 5)-piridinas - Google Patents
2-amino-6-(fenilo sustituido en las posiciones 2, 4, 5)-piridinasInfo
- Publication number
- HN2002000289A HN2002000289A HN2002000289A HN2002000289A HN2002000289A HN 2002000289 A HN2002000289 A HN 2002000289A HN 2002000289 A HN2002000289 A HN 2002000289A HN 2002000289 A HN2002000289 A HN 2002000289A HN 2002000289 A HN2002000289 A HN 2002000289A
- Authority
- HN
- Honduras
- Prior art keywords
- phenyl
- ylamine
- pyridin
- methoxy
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
Abstract
La presente invención se refiere a los compuestos 6 - [4 - (N-metil-3-azetidinoxi)-5-etil-2-metoxi-fenil]-piridin-2-ilamina, 6 - [4 - (N, N-dimetilaminometil )-5-etil-2-metoxi-fenil]-piridin-2-ilamina, 6 - [4 - (N-metilaminometil)-5-etil-2-metoxi-fenil]-piridin-2-ilamina, 6 - [ 4 - (3-azetidinoxi)-5-etil-2-metoxi-fenil]-piridin-2-ilamina y 6 - [4 - (2-dimetilamino-etoxi)-5-etil-2-metoxi-fenil]-piridin -2-ilamina, y las sales farmacéuticamente aceptables de los mismos, a composiciones farmacéuticas que contienen tales compuestos y al uso de tales compuestos como inhibidores de la óxido nítrico sintasa en el tratamiento y prevención de sistema nervioso central y otros trastornos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32825301P | 2001-10-10 | 2001-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2002000289A true HN2002000289A (es) | 2002-12-03 |
Family
ID=23280189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2002000289A HN2002000289A (es) | 2001-10-10 | 2002-10-09 | 2-amino-6-(fenilo sustituido en las posiciones 2, 4, 5)-piridinas |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP1434624B1 (es) |
| JP (1) | JP2005506337A (es) |
| KR (1) | KR20040053157A (es) |
| CN (1) | CN1568207A (es) |
| AP (1) | AP2004003003A0 (es) |
| AR (1) | AR036763A1 (es) |
| AT (1) | ATE344089T1 (es) |
| BG (1) | BG108669A (es) |
| BR (1) | BR0213193A (es) |
| CA (1) | CA2463364A1 (es) |
| CZ (1) | CZ2004450A3 (es) |
| DE (1) | DE60215837T2 (es) |
| DO (1) | DOP2002000467A (es) |
| EA (1) | EA007074B1 (es) |
| EC (1) | ECSP045055A (es) |
| EE (1) | EE200400085A (es) |
| ES (1) | ES2275917T3 (es) |
| GT (1) | GT200200206A (es) |
| HN (1) | HN2002000289A (es) |
| HR (1) | HRP20040260A2 (es) |
| HU (1) | HUP0401678A3 (es) |
| IL (1) | IL161089A0 (es) |
| IS (1) | IS7171A (es) |
| MA (1) | MA27074A1 (es) |
| MX (1) | MXPA04002313A (es) |
| NO (1) | NO20041411L (es) |
| NZ (1) | NZ531591A (es) |
| OA (1) | OA12664A (es) |
| PA (1) | PA8556101A1 (es) |
| PE (1) | PE20030478A1 (es) |
| PL (1) | PL369454A1 (es) |
| SK (1) | SK1642004A3 (es) |
| TN (1) | TNSN04057A1 (es) |
| UY (1) | UY27476A1 (es) |
| WO (1) | WO2003030993A1 (es) |
| ZA (1) | ZA200401747B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232739A1 (en) * | 2001-08-15 | 2003-12-18 | Pfizer Inc. | Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist |
| US20080070952A1 (en) * | 2005-02-21 | 2008-03-20 | Proximagen Ltd., | Inhibition or Treatment of Dyskinesia |
| WO2012084711A1 (en) * | 2010-12-24 | 2012-06-28 | Msd Oss B.V. | N-substituted azetidine derivatives |
| RU2637503C1 (ru) * | 2016-12-30 | 2017-12-05 | Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский государственный университет" (ТГУ, НИ ТГУ) | Способ получения n2-метилдезоксигуанозина |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0891332T3 (da) * | 1996-03-29 | 2004-07-05 | Pfizer | 6-phenylpyridyl-2-aminderivater |
| JP3505189B2 (ja) * | 1997-02-10 | 2004-03-08 | ファイザー・プロダクツ・インク | ２−アミノ−６−（２−置換−４−フェノキシ）−置換ピリジン |
| EE200100611A (et) * | 1999-05-21 | 2003-02-17 | Pfizer Products Inc. | NOS inhibiitorite uued farmatseutilised kombinatsioonid |
-
2002
- 2002-09-23 DO DO2002000467A patent/DOP2002000467A/es unknown
- 2002-09-24 DE DE60215837T patent/DE60215837T2/de not_active Expired - Fee Related
- 2002-09-24 IL IL16108902A patent/IL161089A0/xx unknown
- 2002-09-24 NZ NZ531591A patent/NZ531591A/en unknown
- 2002-09-24 JP JP2003534022A patent/JP2005506337A/ja not_active Withdrawn
- 2002-09-24 AP APAP/P/2004/003003A patent/AP2004003003A0/en unknown
- 2002-09-24 SK SK164-2004A patent/SK1642004A3/sk not_active Application Discontinuation
- 2002-09-24 PL PL02369454A patent/PL369454A1/xx not_active Application Discontinuation
- 2002-09-24 CN CNA028200675A patent/CN1568207A/zh active Pending
- 2002-09-24 CZ CZ2004450A patent/CZ2004450A3/cs unknown
- 2002-09-24 EE EEP200400085A patent/EE200400085A/xx unknown
- 2002-09-24 ES ES02775016T patent/ES2275917T3/es not_active Expired - Lifetime
- 2002-09-24 OA OA1200400093A patent/OA12664A/en unknown
- 2002-09-24 BR BR0213193-5A patent/BR0213193A/pt not_active IP Right Cessation
- 2002-09-24 EA EA200400321A patent/EA007074B1/ru not_active IP Right Cessation
- 2002-09-24 EP EP02775016A patent/EP1434624B1/en not_active Expired - Lifetime
- 2002-09-24 CA CA002463364A patent/CA2463364A1/en not_active Abandoned
- 2002-09-24 MX MXPA04002313A patent/MXPA04002313A/es active IP Right Grant
- 2002-09-24 AT AT02775016T patent/ATE344089T1/de not_active IP Right Cessation
- 2002-09-24 WO PCT/IB2002/003939 patent/WO2003030993A1/en active IP Right Grant
- 2002-09-24 HU HU0401678A patent/HUP0401678A3/hu unknown
- 2002-09-24 KR KR10-2004-7005248A patent/KR20040053157A/ko not_active Application Discontinuation
- 2002-10-04 PE PE2002000987A patent/PE20030478A1/es not_active Application Discontinuation
- 2002-10-08 AR ARP020103790A patent/AR036763A1/es unknown
- 2002-10-08 UY UY27476A patent/UY27476A1/es not_active Application Discontinuation
- 2002-10-09 HN HN2002000289A patent/HN2002000289A/es unknown
- 2002-10-10 PA PA20028556101A patent/PA8556101A1/es unknown
- 2002-10-10 GT GT200200206A patent/GT200200206A/es unknown
-
2004
- 2004-03-03 ZA ZA200401747A patent/ZA200401747B/en unknown
- 2004-03-04 IS IS7171A patent/IS7171A/is unknown
- 2004-03-17 HR HRP20040260 patent/HRP20040260A2/hr not_active Application Discontinuation
- 2004-04-02 NO NO20041411A patent/NO20041411L/no unknown
- 2004-04-06 BG BG108669A patent/BG108669A/xx unknown
- 2004-04-07 TN TNP2004000057A patent/TNSN04057A1/fr unknown
- 2004-04-08 MA MA27619A patent/MA27074A1/fr unknown
- 2004-04-08 EC EC2004005055A patent/ECSP045055A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27592A1 (es) | Nuevo uso | |
| UY27226A1 (es) | Pirazolopirimidinas como agentes terapéuticos | |
| BRPI0407976A (pt) | tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6 | |
| PA8596901A1 (es) | Inhibidores de p38 y metodos de uso de ellos | |
| BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
| CR8861A (es) | Nuevos derivados piperidilo de quinazolina e isoquinolina | |
| BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
| PA8604301A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| DK1791830T3 (da) | Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer | |
| UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| PE20060775A1 (es) | Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa | |
| AR036233A1 (es) | Un compuesto derivado de indol, su uso, procesos para prepararlo y una composicion farmaceutica que lo comprende | |
| UY28059A1 (es) | Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos. | |
| PL378136A1 (pl) | Pirymidyny i triazyny hamujące replikacją wirusa HIV | |
| CL2004000849A1 (es) | Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras. | |
| DK1789398T3 (da) | 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE) | |
| PA8604201A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
| UY27872A1 (es) | Inhibidores de caspasa y usos de los mismos. | |
| BR9811093A (pt) | Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo) | |
| BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| CO5611124A2 (es) | Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos | |
| GT200600397A (es) | Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales | |
| BR0208813A (pt) | Composições contendo imidazotriazinona para a aplicação nasal |